Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 10, 2006

Waters and Advion BioSciences Integrate Technologies

  • Waters and Advion Biosciences successfully completed the evaluation phase of a joint effort to integrate the Advion TriVersa NanoMate chip-based infusion technology with the Waters® Synapt High Definition MS™ System.

    The companies say the collaboration will maximize the amount of information researchers can extract from complex samples by combining the ease-of-use and reproducibility of Advion’s nanoelectrospray chip-based sample introduction technology with the additional dimension of ion mobility-based separation provided by the Waters Synapt™ HDMS System.

    The Synapt HDMS System combines high-sensitivity ion mobility and tandem mass spectrometry to provide information that is beyond the capabilities of conventional mass spectrometers, namely its ability to probe the size and shape of ions, says Alan Millar, HDMS program manager at Waters.

    “A prerequisite for many investigations of this type is the ability to maintain the native conformation of protein or peptide ions into the gas phase. This is typically achieved through the use of neutral pH solvents and low infusion flow rates; an area where the TriVersa NanoMate system can provide demonstrable benefits in terms of ease-of-use and reproducibility,” says Jack Henion, Ph.D., co-founder, CSO, and chairman of Advion BioSciences.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »